We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
ADLM 2025
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Point-of-Care PGx Test Enables Rapid Appropriate Antiplatelet Prescription for Stroke Patients

By LabMedica International staff writers
Posted on 12 Jun 2025

Clopidogrel is an antiplatelet treatment for secondary prevention of minor strokes and transient ischemic attack (TIA), also known as a mini-stroke. CYP2C19 intermediate and poor metabolizers who receive clopidogrel experience reduced platelet inhibition and increased risk for major adverse cardiovascular and cerebrovascular events. Pharmacogenetic testing assists prescribers in selecting tailored treatment and doses that are most effective and avoid those that may cause adverse reactions in an individual with a known genetic variant. This facilitates effective prescription in a clinically relevant timeframe, thereby improving patient outcomes. Now, a rapid point of care (POC) test for CYP2C19 genotyping can effectively guide antiplatelet therapeutics in time-critical settings.

The Genedrive CYP2C19 ID Kit from genedrive plc (Manchester, UK) provides rapid, automated results of CYP2C19 genotypes to inform clinicians on an individual’s metabolizer status according to CPIC guidelines in treatment strategies using therapeutics that are metabolized by CYP2C19. The Genedrive CYP2C19 ID Kit is the only POC genetic test to aid clinicians’ therapeutic treatment decisions for drugs that are metabolized by CYP2C19, and that are specifically affected by DNA variant alleles 2, 3, 4, 8, 17, and 35.


Image: The Genedrive CYP2C19 ID rapid POC test is used in conjunction with the Genedrive system (Photo courtesy of genedrive plc)
Image: The Genedrive CYP2C19 ID rapid POC test is used in conjunction with the Genedrive system (Photo courtesy of genedrive plc)

The test provides rapid, actionable results in approximately 69 minutes, including diplotype and CPIC-coded metabolizer status, enabling personalized treatment for antiplatelet therapies. The non-invasive test uses a single buccal swab and has a simple-to-follow workflow. The Genedrive CYP2C19 ID Kit is used in conjunction with the Genedrive System, featuring a compact benchtop design that allows it to be placed at the POC. Designed to be used in time-critical situations, before treatment prescription, it uses gene detection technology​ to provide automated and easy-to-interpret actionable results.

Related Links:
genedrive plc


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Automated Biochemical Analyzer
iBC 900
New
Sample Transportation System
Tempus1800 Necto

Latest Molecular Diagnostics News

First Blood-Based Test Measures Key Alzheimer's Biomarker in Asymptomatic and Symptomatic Individuals
12 Jun 2025  |   Molecular Diagnostics

Rapid Molecular Diagnostic Device to Detect and Differentiate Ebola and Marburg Virus Species
12 Jun 2025  |   Molecular Diagnostics

New RNA-Based Measure Predicts Mortality Risk and Tracks Aging
12 Jun 2025  |   Molecular Diagnostics



PURITAN MEDICAL